NCT03973853

Brief Summary

Schizophrenia is a mental health issue that affects mostly young adults. The main symptoms are hallucinations, delirium, and agitation, poor social relations, lack of motivation, thought disorganization. Also, patients suffering from schizophrenia encounter important cognitive disorders affecting memory, executive functioning and attention. These cognitive alterations are often linked to social exclusion and stigmatisation. Antipsychotic treatments are effective mainly on the positive dimension of symptoms (hallucinations etc…); however their action is very limited on the cognitive difficulties encountered. Psychosocial techniques can be used to treat the cognitive symptoms, such as cognitive remediation or psychosocial rehabilitation . These cognitive difficulties mainly have an impact on patients' daily life, affecting their abilities to drive, for example. Schizophrenic patients suffer more road accidents than healthy subjects . Thus, considering this information, it appears important to us to address this driving problem for various reasons:

  • Firstly, knowing how to drive is often linked to daily autonomy,
  • Secondly, driving is also linked to keeping an active social network and to work. Patients suffering from schizophrenia often encounter difficulties in learning how to drive which reinforces the stigmatisation and fear of failure. Thus, a specific driving and theory training prior to driving lessons could be a way of helping patients in their cognitive difficulties and pass their driving test. Daily transports mobilize a number of cognitive functions (attentional vigilance, working memory, psychomotor coordination, divided attention, visuo-spatial abilities . Using a driving virtual reality tool could constitute an ecological cognitive remediation tool, by simulating daily driving situations. This "serious game" approach enables us to involve virtual reality in training but also in assessments. The driving simulator allows standardized evaluations and could also become a therapeutic tool of ecological cognitive remediation. This study thus appears interesting in order to develop road safety and daily autonomy.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2019

Shorter than P25 for not_applicable schizophrenia

Geographic Reach
1 country

2 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 4, 2019

Completed
21 days until next milestone

Study Start

First participant enrolled

June 25, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2019

Completed
Last Updated

March 7, 2025

Status Verified

March 1, 2025

Enrollment Period

6 months

First QC Date

April 25, 2019

Last Update Submit

March 4, 2025

Conditions

Keywords

virtual realitysocial autonomyroad safetydriving abilitiesschizophreniacognitive functioning

Outcome Measures

Primary Outcomes (1)

  • Social Autonomy

    the primary outcome will be the modification before and after intervention of the total score on the Social Autonomy scale. It is obtained by 5 domains (personal health, everyday life, money, social relationships, and affective life).

    7 months

Secondary Outcomes (4)

  • Rosenberg Self-esteem

    7 months

  • World Health Organization Quality of Life Assessment (WHOQLOL-BREF)

    7 months

  • The positive and negative syndrome (PANSS)

    7 months

  • Car Simulator Evaluation Test

    7 months

Study Arms (2)

Active group with virtual reality stimulation

EXPERIMENTAL

The subjects in this arm will undertake 14 sessions of virtual reality stimulation. The program will be delivered by a nurse, trained to the use of such a tool, and familiar with cognitive remediation techniques. Before and after these 14 sessions, social autonomy, daily life skills, cognitive domains and self-esteem will be measured

Behavioral: Virtual reality driving stimulation program

Treatment as Usual group (TAU)

PLACEBO COMPARATOR

Patients in this group will carry on benefiting from their usual care with no additional program. They will be assessed before and after a 3 month period for social autonomy, daily life skills, cognitive domains and self-esteem.

Behavioral: TAU

Interventions

This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.

Active group with virtual reality stimulation
TAUBEHAVIORAL

This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.

Treatment as Usual group (TAU)

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Diagnostic of Schizophrenia according to a DSM-5 criteria
  • Aged between 18-50 years
  • Enrolled in an empowerment project
  • Stable clinical status, without treatment modification for 3 months
  • Capacity to consent
  • Affiliated to a social security scheme

You may not qualify if:

  • Opposition of patient or legal guardian
  • Background of head trauma, neurological pathology with cerebral repercussions or severe somatic or ocular disease not stabilized or resulting in pain\> 3 months
  • Visual disorders related to surgery or known ocular pathology leading to visual loss or visual field restriction
  • Mental retardation \< 80

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital le vinatier

Bron, 69677, France

Location

Hopital Vinatier

Bron, 69678, France

Location

MeSH Terms

Conditions

Schizophrenia

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • ROMAIN REY, PH

    CH Le Vinatier

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2019

First Posted

June 4, 2019

Study Start

June 25, 2019

Primary Completion

December 30, 2019

Study Completion

December 30, 2019

Last Updated

March 7, 2025

Record last verified: 2025-03

Locations